AbbVie Inc.
ABBVHIGH VELOCITYDEAL MODE DOMINANTAbbVie Inc. reads as an High Velocity (composite 78/100); Transformational Buyer deploying $18B across 1 disclosed transactions, down 54% vs the prior cycle · primary market Healthcare, ranked #2 on disclosed spend.
Lens
Disclosed M&A capital (2023–2025)
$18B
vs $39.1B in 2020–2022
Disclosed transactions
1
3/3 active fiscal years in window
Buyer archetype
Transformational Buyer
Episodic but very large disclosed transactions drive the profile.
Composite score
78
High Velocity dominates · Deal Mode Dominant
Behavioral posture, nine reads.
Each index scores the issuer 0–100 against an EDGAR-anchored definition. Scores ≥ threshold elevate the issuer into the index's constituent set; the dominant index drives the masthead label.
Active Acquirer
Companies actively deploying disclosed capital into M&A
- $72.7B disclosed buyer spend
- Filed within 18d
Buyer Cadence
Buyer-side companies with recent filing activity
- Filed within 18d
- 193 8-Ks
Target Probability
Issuers showing target-side patterns from filings
- 1 activism filings
Spin/Carve
Issuers showing spin-off, carve-out, or sum-of-parts posture
- 7 spin pre-registrations
- Latest event 14y ago; heavily discounted
- 1 activism filings
Pressure Watch
Issuers facing activism, governance, or control pressure
- 1 activism filings
- Latest activism 8.6y ago; heavily discounted
Distress Watch
Issuers showing financial-distress filing patterns
- 1 activism filings
Restatement Risk
Issuers with accounting-integrity flags from filings
- 2 auditor changes
- Latest event 13y ago; heavily discounted
Capital Velocity
DominantIssuers with the highest filing-activity intensity
- 193 8-Ks
- Filed within 18d
- 5 form types
Quiet Power
Large issuers with low signal volume and clean disclosure cadence
- Enterprise value $420B
- 10-Q 18d ago
- 4 active signals
Capital cadence.
Ten-year disclosed M&A activity. Bars show spend ($MM); ticks show recorded transaction count. Disclosure tier annotated where v6 audited corpus carries an entry.
Disclosed spend $MM Disclosed transactions (right axis)Peak spend year: $38,260M · Peak count: 2
| FY | Disclosed buys | Disclosed spend | Avg ticket | Audited tier |
|---|---|---|---|---|
| 2025 | 1 | $204M | $204M | N/A |
| 2024 | N/A | $17.5B | N/A | N/A |
| 2023 | N/A | $255M | N/A | N/A |
| 2022 | 1 | $255M | $255M | N/A |
| 2021 | 1 | $535M | $535M | N/A |
| 2020 | 2 | $38.3B | $19.1B | N/A |
Strategy posture.
The buyer's playbook in terms of strategic archetype: what each disclosed move says about how they're deploying capital.
Archetype mix
- Platform20%
- Technology Acquisition20%
- Bolt On20%
- Geographic Expansion20%
- Tuck In20%
Strategy keywords
Terms recurring across recent 10-K acquisition disclosures.
- platform
- bolt_on
- technology_acquisition
- geographic_expansion
- tuck_in
- horizontal_consolidation
Filing language.
Direct excerpts from acquisition disclosures and strategy sections: the verbs the buyer chose, in the filings they signed.
“AbbVie's strategy has focused on delivering strong financial results, maximizing the benefits of the Allergan acquisition, advancing and investing in its pipeline and returning value to shareholders”
“Following the closing of the Allergan acquisition in 2020, AbbVie implemented an integration plan designed to reduce costs, integrate and optimize the combined organization”
“The acquisition complements AbbVie’s neuroscience portfolio, adding a wide range of potentially best-in-class assets”
“The acquisition of ImmunoGen further builds on AbbVie's existing solid tumor pipeline of novel targeted therapies”
“continued investment in AbbVie’s on-market brands”
Market context.
Where this issuer sits inside its SE-Cluster rollup wedge, with disclosed-spend rank plus trading comparables against the public peer set.
Primary market
Healthcare
- Market spend (2023–2025)
- $195B
- Market spend (2020–2022)
- $253.6B
- Recent vs prior
- −23%
- Issuer rank in market
- #2 of 391
- Share of market capital
- 8.2%
Valuation positioning
ABBV trades at a +10.4-turn premium to the Healthcare peer median of 12.9×.
- EV / Revenue
- 6.7×
- Net debt / EBITDA
- 3.1×
- Peer median EV / EBITDA
- 12.9×
Trading comparables
FMP market data · 2026-05-10
| Company | EV / EBITDA | EV / Rev | Net debt / EBITDA | Revenue | M&A 2023–2025 |
|---|---|---|---|---|---|
AbbVie Inc.ABBV | 23.4× | 6.7× | 3.1× | $62.8B | $18B |
| 17.2× | 0.9× | 1.9× | $449.7B | $28.1B | |
| 15.0× | 5.1× | 1.2× | $60.4B | $19M | |
Amgen Inc.AMGN | 12.9× | 6.0× | 2.6× | $37.2B | $26.7B |
| 11.7× | 0.5× | 2.5× | $200.4B | $6.4B | |
| 9.3× | 1.9× | 2.8× | $76.4B | $1.3B |
Trading multiples from FMP market data; disclosed M&A spend from the SE-Cluster EDGAR 10-K corpus. Peer set = top disclosed buyers in Healthcare. Bars scaled to the highest EV/EBITDA in the set.
Target landscape.
Public-issuer targets that fit this buyer's archetype and target categories from filing-derived signal. Scores reflect cross-signal fit; reasons cite the EDGAR-anchored facts that drove the match.
No qualifying public-issuer targets surfaced from the current signal mix.
Stated target categories
No target categories enumerated in the audited corpus for this issuer.
Filing activity & signal stream.
Filing cadence and event-driven signals visible on EDGAR. The signal stream below is curated from restatement / spin-carve / activism categories, providing context for any near-term call.
Filing cadence
- 10-K (annual)152026-02-20
- 10-Q (quarterly)402026-05-08
- 8-K (event)1932026-04-29
- Proxy / DEF 14A252026-03-23
- Activism (13D / DFAN / PREC)12017-10-06
Signals on file
- elevated
Auditor change
2013-03-192 Item 4.01 filings on file; certifying accountant change.
- elevated
Spin registration
2012-11-307 Form 10-12 filings on file; pre-spin registration.
- elevated
Activism on file
2017-10-061 activist filing on file (13D, DFAN14A, PREC14A series).
- info
Signal
Serial acquisition history
- info
Signal
10-K strategy themes
- info
Signal
Spin/Carve candidate
Audited corpus.
No audited record on file for this CIK in the current v6 corpus.
This issuer has not been extracted into the v6 audited acquirer corpus yet. The brief above pulls from ranking-level aggregates and issuer-index signal only.